Andrew Schiermeier, Intellia COO
Blackstone throws $250M behind Intellia-Cellex quest to combine CRISPR and controllable CAR-Ts
So here’s how Blackstone is spending its $4.6 billion biopharma pot.
The private equity firm announced Tuesday they were teaming with the CRISPR biotech …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
